Torcetrapib

Torcetrapib (CP-529414, Pfizer) was a drug developed by Pfizer to treat hypercholesterolemia and prevent cardiovascular disease.

In December 2006, Pfizer Inc. halted the development of torcetrapib, a cholesterol drug, after the data-safety monitoring board observed an increase in deaths and cardiovascular events among patients. Complete results from the study, known as Illuminate, will be published in the New England Journal of Medicine.